Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Onco
Special Issues
Targeting of Tumor Dormancy Pathway
share announcement

Targeting of Tumor Dormancy Pathway

A special issue of Onco (ISSN 2673-7523).

Deadline for manuscript submissions: 31 October 2024 | Viewed by 1037

Special Issue Editors

Dr. Athanassios Kotsinas

E-Mail Website
Guest Editor
Laboratory of Histology-Embryology, Faculty of Medicine, National & Kapodistrian University of Athens, 75 Mikras Asias Street, Goudi, 11527 Athens, Greece
Interests: DNA polymorphisms; RNA; miRNAs; carcinogenesis; bioinformatics; DNA damage; cell cycle; cancer
Dr. Constantin N. Baxevanis

E-Mail Website
Guest Editor
Cancer Immunology and Immunotherapy Center, Cancer Research Center, Saint Savas Cancer Hospital, 171 Alexandras Av., 11522 Athens, Greece
Interests: cancer immunology; cancer immunotherapy; biomarkers; precision oncology; immune resistance; cancer vaccines; immune escape; immune checkpoint inhibitors
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Dormant tumor cells, also known as minimal residual disease, represent a population of cancer cells that have entered a state of growth arrest, typically after primary tumor removal or during periods of remission. This dormant state allows them to evade conventional cancer therapies, such as chemotherapy or radiation, which primarily target actively dividing cells. It is generally thought that dormant tumor cells have the potential to reactivate and give rise to metastatic tumors years or even decades after initial treatment. However, from another perspective, keeping tumor cells silent for decades can be regarded as tantamount to cure. From both perspectives, it is important to understand the mechanisms underlying dormancy. Keeping tumor cells dormant for indefinite periods of time could form a new strategy of cancer treatment. This Special Issue will highlight the current state of the knowledge in tumor dormancy, targeting of tumor dormancy pathways, and future prospects for exploiting tumor dormancy for cancer therapies.

Dr. Athanassios Kotsinas
Dr. Constantin N. Baxevanis
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Onco is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • dormant tumor cells
  • conventional cancer therapies
  • cancer therapies
  • chemotherapy
  • radiation
  • tumor dormancy
  • targeting of tumor dormancy pathways

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Other

9 pages, 1755 KiB  
Commentary
When Therapy-Induced Cancer Cell Apoptosis Fuels Tumor Relapse
by Razmik Mirzayans
Onco 2024, 4(1), 37-45; https://doi.org/10.3390/onco4010003 - 04 Feb 2024
Viewed by 680
Abstract
Most therapeutic strategies for solid tumor malignancies are designed based on the hypothesis that cancer cells evade apoptosis to exhibit therapy resistance. This is somewhat surprising given that clinical studies published since the 1990s have demonstrated that increased apoptosis in solid tumors is [...] Read more.
Most therapeutic strategies for solid tumor malignancies are designed based on the hypothesis that cancer cells evade apoptosis to exhibit therapy resistance. This is somewhat surprising given that clinical studies published since the 1990s have demonstrated that increased apoptosis in solid tumors is associated with cancer aggressiveness and poor clinical outcome. This is consistent with more recent reports demonstrating non-canonical (pro-survival) roles for apoptotic caspases, including caspase 3, as well as the ability of cancer cells to recover from late stages of apoptosis via a process called anastasis. These activities are essential for the normal development and maintenance of a healthy organism, but they also enable malignant cells (including cancer stem cells) to resist anticancer treatment and potentially contribute to clinical dormancy (minimal residual disease). Like apoptosis, therapy-induced cancer cell dormancy (durable proliferation arrest reflecting various manifestations of genome chaos) is also not obligatorily a permanent cell fate. However, as briefly discussed herein, compelling pre-clinical studies suggest that (reversible) dormancy might be the “lesser evil” compared to treacherous apoptosis. Full article
(This article belongs to the Special Issue Targeting of Tumor Dormancy Pathway)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop